TORONTO, CN: MaRS EXCITE, a commercial-stage, informatics based precision medicine company providing treatment decision support to clinicians for behavioral health conditions has announced its partnership with Assurex Canada, a medical company that treats patients with mental health disorders.
The partnership aims at offering precision medicine to Canadians suffering from depression and schizophrenia. Assurex Canada therefore aims at offering medication for behavioural health conditions for patients through genetic tests called the GeneSight. This technology which is based on a proprietary informatics platform is capable of treating depression and schizophrenia. Besides these the technology also relieves patients from anxiety, posttraumatic stress disorder (PTSD), bipolar disorder, and other behavioral health conditions.
Developed in the Assurex Health clinical laboratory, GeneSight is based on patented technology licensed from Mayo Clinic and Cincinnati Children’s Hospital Medical Center. It helps healthcare providers to more quickly find an effective treatment for their patientsso as to save them from experiencing side effects that often come from taking antidepressants and antipsychotics.
“GeneSight represents the first genetic testing technology to be evaluated through the EXCITE program. To convince healthcare providers to integrate genetic testing tools such as GeneSight into their routine decision-making – and to convince payers to reimburse this innovation – will take more than just data on safety and effectiveness. It requires a compelling case be made to primary care health professionals on the value of incorporating this genetic test into the way they work today,” saysDr.ZaynaKhayat, Director,MaRS EXCITE program.